Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 9NIH 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 38Breast 4Lymphoid 3Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2Leukemia 2Anemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Epoetin Alfa × Other hematologic neoplasm × Clear all
NCT00261677 2011-05-23

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Ortho Biotech Products, L.P.

Phase 3 Completed
224 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
195 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡